Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics
Recurrent C. diff study now enrollingAn open-label study of SER-109
Seres announces positive topline results for SER-109 SER-109 met primary endpoint in Phase 3 study in C. difficile